CY2021019I1 - Παραγωγα ν4-φαινυλ-κιναζολινο-4-αμινης και σχετικες ενωσεις ως αναστολεις υποδοχεα κινασης τυροσινης τυπου i erbb για τη θεραπεια υπερπολλαπλασιαστικων ασθενειων - Google Patents

Παραγωγα ν4-φαινυλ-κιναζολινο-4-αμινης και σχετικες ενωσεις ως αναστολεις υποδοχεα κινασης τυροσινης τυπου i erbb για τη θεραπεια υπερπολλαπλασιαστικων ασθενειων

Info

Publication number: CY2021019I1
Authority: CY; Cyprus
Prior art keywords: hyperplovarative; quinazolino; diseases; phenyl; treatment
Prior art date: 2005-11-15

Application number

CY2021019C

Other languages

English (en)

Other versions

CY2021019I2 (el

Original Assignee

Array Biopharma, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-15

Filing date

2021-07-09

Publication date

2021-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38022019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2021019(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2021-07-09 Application filed by Array Biopharma, Inc. filed Critical Array Biopharma, Inc.

2021-10-15 Publication of CY2021019I1 publication Critical patent/CY2021019I1/el

2021-12-31 Publication of CY2021019I2 publication Critical patent/CY2021019I2/el

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Endocrinology (AREA)
Neurology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Mycology (AREA)
Microbiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Virology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)

CY2021019C 2005-11-15 2021-07-09 Παραγωγα ν4-φαινυλ-κιναζολινο-4-αμινης και σχετικες ενωσεις ως αναστολεις υποδοχεα κινασης τυροσινης τυπου i erbb για τη θεραπεια υπερπολλαπλασιαστικων ασθενειων CY2021019I2 (el)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US73628905P	2005-11-15	2005-11-15
US81701906P	2006-06-28	2006-06-28
EP06837728A EP1971601B1 (en)	2005-11-15	2006-11-15	N4-phenyl-quinazoline-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
PCT/US2006/044431 WO2007059257A2 (en)	2005-11-15	2006-11-15	N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases

Publications (2)

Publication Number	Publication Date
CY2021019I1 true CY2021019I1 (el)	2021-10-15
CY2021019I2 CY2021019I2 (el)	2021-12-31

Family

ID=38022019

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CY20101100043T CY1110583T1 (el)	2005-11-15	2010-01-15	Παραγωγα ν4-φαινυλ-κιναζολινο-4-αμινης και σχετικες ενωσεις ως αναστολεις υποδοχεα κινασης τυροσινης τυπου i erbb για τη θεραπεια υπερπολλαπλασιαστικων ασθενειων
CY20111100696T CY1112754T1 (el)	2005-11-15	2011-07-15	Μεθοδοι και ενδιαμεσα για την παρασκευη παραγωγων ν4-φαινυλ-κιναζολιν-4-αμινης
CY2021019C CY2021019I2 (el)	2005-11-15	2021-07-09	Παραγωγα ν4-φαινυλ-κιναζολινο-4-αμινης και σχετικες ενωσεις ως αναστολεις υποδοχεα κινασης τυροσινης τυπου i erbb για τη θεραπεια υπερπολλαπλασιαστικων ασθενειων

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
CY20101100043T CY1110583T1 (el)	2005-11-15	2010-01-15	Παραγωγα ν4-φαινυλ-κιναζολινο-4-αμινης και σχετικες ενωσεις ως αναστολεις υποδοχεα κινασης τυροσινης τυπου i erbb για τη θεραπεια υπερπολλαπλασιαστικων ασθενειων
CY20111100696T CY1112754T1 (el)	2005-11-15	2011-07-15	Μεθοδοι και ενδιαμεσα για την παρασκευη παραγωγων ν4-φαινυλ-κιναζολιν-4-αμινης

Country Status (28)

Country	Link
US (6)	US8648087B2 (el)
EP (2)	EP2090575B1 (el)
JP (2)	JP5134548B2 (el)
KR (1)	KR101086967B1 (el)
CN (2)	CN102887891B (el)
AT (2)	ATE507224T1 (el)
AU (2)	AU2006315383B2 (el)
BR (2)	BRPI0618668B1 (el)
CA (2)	CA2755268C (el)
CY (3)	CY1110583T1 (el)
DE (2)	DE602006021645D1 (el)
DK (2)	DK2090575T3 (el)
ES (2)	ES2364901T3 (el)
FI (1)	FIC20210022I1 (el)
FR (1)	FR21C1031I2 (el)
HU (1)	HUS2100028I1 (el)
IL (2)	IL239149A (el)
LT (1)	LTC1971601I2 (el)
LU (1)	LUC00217I2 (el)
NL (1)	NL301113I2 (el)
NO (1)	NO342413B1 (el)
PL (2)	PL2090575T3 (el)
PT (2)	PT2090575E (el)
RU (2)	RU2428421C2 (el)
SG (1)	SG152230A1 (el)
SI (2)	SI2090575T1 (el)
WO (1)	WO2007059257A2 (el)
ZA (1)	ZA200804498B (el)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103664802B (zh)	2003-08-14	2015-08-05	阿雷生物药品公司	作为受体酪氨酸激酶抑制剂的喹唑啉类似物
US7501427B2 (en)	2003-08-14	2009-03-10	Array Biopharma, Inc.	Quinazoline analogs as receptor tyrosine kinase inhibitors
GB0420722D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
ATE507224T1 (de)	2005-11-15	2011-05-15	Array Biopharma Inc	Verfahren und zwischenverbindungen zur herstellung von n4-phenyl-quinazolin-4-amin derivaten
TWI417095B (zh)	2006-03-15	2013-12-01	Janssen Pharmaceuticals Inc	１，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
US7547781B2 (en)	2006-09-11	2009-06-16	Curis, Inc.	Quinazoline based EGFR inhibitors containing a zinc binding moiety
JP5580592B2 (ja)	2006-09-11	2014-08-27	キュリス，インコーポレイテッド	亜鉛結合部分を含むキナゾリン系ｅｇｆｒインヒビター
JP2010502743A (ja) *	2006-09-11	2010-01-28	キュリス，インコーポレイテッド	抗増殖薬剤としての多機能性低分子
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EP2162445B1 (en) *	2007-06-05	2013-11-27	Takeda Pharmaceutical Company Limited	Heterobicyclic compounds as kinase inhibitors
US9114138B2 (en)	2007-09-14	2015-08-25	Janssen Pharmaceuticals, Inc.	1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
EA016969B1 (ru)	2007-09-14	2012-08-30	Аддекс Фарма С.А.	1,3-двузамещенные-4-фенил-1н-пиридин-2-оны
ATE516272T1 (de)	2007-09-14	2011-07-15	Ortho Mcneil Janssen Pharm	1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
JP5433582B2 (ja)	2007-11-14	2014-03-05	ジャンセンファーマシューティカルズ，インコーポレイテッド．	イミダゾ［１，２−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用
CN102143955B (zh)	2008-09-02	2013-08-14	Omj制药公司	作为代谢型谷氨酸受体调节剂的3-氮杂二环[3.1.0]己烷衍生物
RU2011119478A (ru)	2008-10-14	2012-11-27	Нин Си	Соединения и способы применения
AU2009304293B2 (en)	2008-10-16	2012-04-26	Addex Pharma S.A.	Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
CA2744138C (en)	2008-11-28	2015-08-11	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
AU2009326149B2 (en)	2008-12-11	2014-01-16	Respivert Limited	P38 MAP kinase inhibitors
NZ596053A (en)	2009-05-12	2013-05-31	Janssen Pharmaceuticals Inc	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh)	2009-05-12	2015-04-29	杨森制药有限公司	1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
US8586581B2 (en)	2009-12-17	2013-11-19	Hoffmann-La Roche Inc	Ethynyl compounds useful for treatment of CNS disorders
WO2011082271A2 (en)	2009-12-30	2011-07-07	Arqule, Inc.	Substituted triazolo-pyrimidine compounds
CN102382106A (zh)	2010-08-30	2012-03-21	黄振华	苯胺取代的喹唑啉衍生物
EP2661435B1 (en)	2010-11-08	2015-08-19	Janssen Pharmaceuticals, Inc.	1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US9012448B2 (en)	2010-11-08	2015-04-21	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9271967B2 (en)	2010-11-08	2016-03-01	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
CA2822357A1 (en)	2010-12-22	2012-06-28	Abbvie Inc.	Hepatitis c inhibitors and uses thereof
JP2014156400A (ja) *	2011-05-24	2014-08-28	Astellas Pharma Inc	腫瘍の画像診断用標識誘導体
JP2014530243A (ja) *	2011-10-14	2014-11-17	アレイバイオファーマ、インコーポレイテッド	Ａｒｒｙ−３８０の多形体、選択的ｈｅｒｂ２阻害剤、およびそれらを含有する薬学的組成物
SI2765990T1 (sl)	2011-10-14	2017-11-30	Array Biopharma, Inc.	Trdna disperzija
HRP20180659T1 (hr)	2012-03-23	2018-06-01	Array Biopharma, Inc.	Disperzija amorfne krutine, namijenjena upotrebi u liječenju raka na mozgu
NO2964638T3 (el) *	2013-03-06	2018-01-06
CA2903288C (en) *	2013-03-15	2021-09-21	Deciphera Pharmaceuticals, Llc	N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
ES2819398T3 (es)	2013-07-18	2021-04-15	Taiho Pharmaceutical Co Ltd	Agente terapéutico para el cáncer resistente al inhibidor de FGFR
EP3023100B1 (en)	2013-07-18	2019-03-13	Taiho Pharmaceutical Co., Ltd.	Antitumor drug for intermittent administration of fgfr inhibitor
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR102461134B1 (ko)	2014-01-21	2022-10-28	얀센 파마슈티카 엔.브이.	대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
LT3431106T (lt)	2014-01-21	2021-02-10	Janssen Pharmaceutica Nv	Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
JP6559785B2 (ja)	2014-12-15	2019-08-14	ザリージェンツオブザユニバーシティオブミシガン	Ｅｇｆｒ及びｐｉ３ｋの小分子阻害剤
RU2672563C1 (ru)	2015-03-31	2018-11-16	Тайхо Фармасьютикал Ко., Лтд.	Кристаллы 3,5-дизамещенного бензолалкинильного соединения
CN107141293B (zh) *	2016-03-01	2022-09-23	上海医药集团股份有限公司	一种含氮杂环化合物、制备方法、中间体、组合物和应用
US11883404B2 (en)	2016-03-04	2024-01-30	Taiho Pharmaceuticals Co., Ltd.	Preparation and composition for treatment of malignant tumors
EP3424505A4 (en)	2016-03-04	2019-10-16	Taiho Pharmaceutical Co., Ltd.	PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
CN106117182B (zh) *	2016-06-20	2019-08-30	中国药科大学	喹唑啉-n-苯乙基四氢异喹啉类化合物及其制备方法和应用
EP3508482B1 (en) *	2016-09-01	2020-12-16	Nanjing Transthera Biosciences Co. Ltd.	Inhibitors of fibroblast growth factor receptor and use thereof
ES2873377T3 (es)	2016-09-22	2021-11-03	Inst Nat Sante Rech Med	Procedimientos y composiciones farmacéuticas para el tratamiento de cáncer de pulmón
WO2018121758A1 (zh) *	2016-12-30	2018-07-05	南京明德新药研发股份有限公司	作为egfr抑制的喹唑啉类化合物
KR20200014298A (ko)	2017-04-28	2020-02-10	시애틀 지네틱스, 인크.	Her2 양성 암의 치료
EP3677583A4 (en) *	2017-09-01	2021-07-21	Shanghai Pharmaceuticals Holding Co., Ltd.	NITROGENOUS HETEROCYCLIC COMPOUND, METHOD OF PREPARATION, INTERMEDIATE, COMPOSITION AND APPLICATION
AU2019239404B2 (en)	2018-03-19	2021-12-23	Taiho Pharmaceutical Co., Ltd.	Pharmaceutical composition including sodium alkyl sulfate
TWI811358B (zh) *	2018-05-08	2023-08-11	大陸商迪哲（江蘇）醫藥股份有限公司	ＥｒｂＢ受體抑制劑
CN112105618B (zh) *	2018-05-08	2022-05-31	南京明德新药研发有限公司	作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
EP4360713B1 (en) *	2018-09-18	2024-10-30	F. Hoffmann-La Roche AG	Quinazoline derivatives as antitumor agents
CN109942576B (zh) *	2019-03-07	2020-09-11	上海工程技术大学	Irbinitinib及中间体的制备方法
CN111825604A (zh) *	2019-04-16	2020-10-27	宁波药腾医药科技有限公司	一种图卡替尼及其中间产物的合成方法
WO2021088987A1 (zh) *	2019-11-08	2021-05-14	南京明德新药研发有限公司	作为选择性her2抑制剂的盐型、晶型及其应用
WO2021156178A1 (en)	2020-02-03	2021-08-12	Boehringer Ingelheim International Gmbh	[1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
JP7626774B2 (ja)	2020-02-03	2025-02-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
AU2020435503B2 (en) *	2020-03-13	2025-02-20	F. Hoffmann-La Roche Ag	ErbB receptor inhibitors as anti-tumor agents
US11608343B2 (en)	2020-04-24	2023-03-21	Boehringer Ingelheim International Gmbh	Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
TW202214641A (zh)	2020-06-30	2022-04-16	美商艾瑞生藥股份有限公司	Ｈｅｒ２突變抑制劑
KR20230155422A (ko)	2020-12-22	2023-11-10	메카니스틱 테라퓨틱스 엘엘씨	Egfr 및/또는 pi3k 억제제로서의 치환된 아미노벤질헤테로아릴 화합물
US20240116921A1 (en) *	2020-12-22	2024-04-11	Enliven Therapeutics, Inc.	Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2
AU2022238571A1 (en)	2021-03-18	2023-09-14	Seagen Inc.	Selective drug release from internalized conjugates of biologically active compounds
CA3213079A1 (en)	2021-04-13	2022-10-20	Kristin Lynne ANDREWS	Amino-substituted heterocycles for treating cancers with egfr mutations
IL309252A (en) *	2021-06-26	2024-02-01	Array Biopharma Inc	Inhibitors of HER2 mutations
KR102598580B1 (ko) *	2021-07-16	2023-11-06	한양대학교 에리카산학협력단	니트로알켄 화합물의 신규 제조방법
WO2023081637A1 (en)	2021-11-02	2023-05-11	Enliven Therapeutics, Inc.	Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
CN118715216A (zh)	2022-03-28	2024-09-27	江苏恒瑞医药股份有限公司	含氮杂环类化合物、其制备方法及其在医药上的应用
CN117384162A (zh) *	2022-05-17	2024-01-12	浙江文达医药科技有限公司	选择性her2抑制剂
WO2024027695A1 (zh) *	2022-08-04	2024-02-08	微境生物医药科技(上海)有限公司	作为her2抑制剂的化合物
CN115650975B (zh) *	2022-08-23	2024-07-02	四川大学华西医院	一种靶向降解人表皮生长因子受体2的蛋白降解靶向嵌合体化合物及其应用
WO2025034912A2 (en)	2023-08-07	2025-02-13	Cogent Biosciences, Inc.	Compounds for fgfr inhibition
WO2025067396A1 (zh) *	2023-09-27	2025-04-03	江苏恒瑞医药股份有限公司	一种喹唑啉衍生物的可药用盐、其结晶形式及用途
WO2025067398A1 (zh) *	2023-09-27	2025-04-03	江苏恒瑞医药股份有限公司	一种喹唑啉衍生物的结晶形式及其制备方法
CN118084901A (zh) *	2023-12-15	2024-05-28	江苏希迪制药有限公司	妥卡替尼的合成方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4029792A (en)	1972-02-29	1977-06-14	Pfizer Inc.	(2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr)	1972-02-29	1973-08-27	Pfizer	Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
DE2653005A1 (de) *	1975-12-03	1977-06-08	Sandoz Ag	Neue organische verbindungen, ihre verwendung und herstellung
US6743782B1 (en)	1987-10-28	2004-06-01	Wellstat Therapeutics Corporation	Acyl deoxyribonucleoside derivatives and uses thereof
US5204348A (en)	1988-10-06	1993-04-20	Mitsui Toatsu Chemicals Inc.	Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components
CA1340821C (en)	1988-10-06	1999-11-16	Nobuyuki Fukazawa	Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5517680A (en)	1992-01-22	1996-05-14	Ericsson Inc.	Self correction of PST simulcast system timing
US5502187A (en)	1992-04-03	1996-03-26	The Upjohn Company	Pharmaceutically active bicyclic-heterocyclic amines
WO1995010506A1 (en) *	1993-10-12	1995-04-20	The Du Pont Merck Pharmaceutical Company	1n-alkyl-n-arylpyrimidinamines and derivatives thereof
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
TW321649B (el) *	1994-11-12	1997-12-01	Zeneca Ltd
US5543523A (en)	1994-11-15	1996-08-06	Regents Of The University Of Minnesota	Method and intermediates for the synthesis of korupensamines
GB9424233D0 (en)	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
AR004010A1 (es)	1995-10-11	1998-09-30	Glaxo Group Ltd	Compuestos heterociclicos
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
HUP9901155A3 (en)	1996-02-13	2003-04-28	Astrazeneca Ab	Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
ATE211134T1 (de)	1996-03-05	2002-01-15		4-anilinochinazolin derivate
CN1145614C (zh)	1996-04-12	2004-04-14	沃尼尔·朗伯公司	酪氨酸激酶的不可逆抑制剂，其制药用途及药物组合物
ES2186908T3 (es)	1996-07-13	2003-05-16	Glaxo Group Ltd	Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas.
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
US6225318B1 (en)	1996-10-17	2001-05-01	Pfizer Inc	4-aminoquinazolone derivatives
GB9714249D0 (en)	1997-07-08	1997-09-10	Angiogene Pharm Ltd	Vascular damaging agents
ZA986732B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
DE19735682A1 (de)	1997-08-19	1999-02-25	Basf Ag	Verfahren zur Herstellung von 3-Isopropyl-1H-2,1,3-benzothiadiazin-4(3H)-on-2,2-dioxid
SK6652000A3 (en)	1997-11-11	2002-05-09	Pfizer Prod Inc	Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
EP1066039A4 (en)	1998-03-02	2003-02-26	Cocensys Inc	SUBSTITUTED QUINAZOLINE AND THEIR ANALOGS AND USES
US6017922A (en)	1998-05-18	2000-01-25	U.S. Bioscience, Inc.	Thermally stable trimetrexates and processes for producing the same
IL143089A0 (en)	1998-11-19	2002-04-21	Warner Lambert Co	N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
GB9900334D0 (en)	1999-01-07	1999-02-24	Angiogene Pharm Ltd	Tricylic vascular damaging agents
ATE302193T1 (de)	1999-01-13	2005-09-15	Warner Lambert Co	Benzoheterozyklen und ihre verwendung als mek inhibitoren
GB9900752D0 (en)	1999-01-15	1999-03-03	Angiogene Pharm Ltd	Benzimidazole vascular damaging agents
GB9910577D0 (en)	1999-05-08	1999-07-07	Zeneca Ltd	Chemical compounds
EE200200149A (et)	1999-09-21	2003-04-15	Astrazeneca Ab	Kinasoliinühendid ja neid sisaldavad ravimkoostised
CN1431999A (zh)	2000-05-31	2003-07-23	阿斯特拉曾尼卡有限公司	具有血管损伤活性的吲哚衍生物
AU2001252463A1 (en)	2000-06-06	2001-12-17	Pfizer Products Inc.	Thiophene derivatives useful as anticancer agents
DE60108754T2 (de)	2000-06-22	2005-06-23	Pfizer Products Inc., Groton	Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
DK1294715T3 (da)	2000-06-30	2007-06-04	Glaxo Group Ltd	Quinazolinditosylatsaltforbindelser
SK52003A3 (en)	2000-07-07	2003-07-01	Angiogene Pharm Ltd	Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same
KR20030014425A (ko)	2000-07-07	2003-02-17	앤지오젠 파마슈티칼스 리미티드	혈관 손상제인 콜치놀 유도체
US7253184B2 (en)	2000-11-02	2007-08-07	Astrazeneca Ab	4-Substituted quinolines as antitumor agents
SE0100569D0 (sv)	2001-02-20	2001-02-20	Astrazeneca Ab	New compounds
AU2002338286A1 (en)	2001-04-10	2002-10-28	Leo Pharma A/S	Novel aminophenyl ketone derivatives
GB0126433D0 (en)	2001-11-03	2002-01-02	Astrazeneca Ab	Compounds
US20050043336A1 (en)	2001-11-03	2005-02-24	Hennequin Laurent Francois Andre	Quinazoline derivatives as antitumor agents
US6756006B1 (en)	2002-03-05	2004-06-29	Peter Levijoki	Method of forming sculptured designs onto a substrate
US7235537B2 (en)	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
US6924285B2 (en)	2002-03-30	2005-08-02	Boehringer Ingelheim Pharma Gmbh & Co.	Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7488823B2 (en)	2003-11-10	2009-02-10	Array Biopharma, Inc.	Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
CA2514479A1 (en)	2003-01-23	2004-08-05	T.K. Signal Ltd.	Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
PE20040945A1 (es)	2003-02-05	2004-12-14	Warner Lambert Co	Preparacion de quinazolinas substituidas
US7135575B2 (en)	2003-03-03	2006-11-14	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
BRPI0410720A (pt)	2003-05-27	2006-06-20	Pfizer Prod Inc	quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase
WO2005007083A2 (en)	2003-06-18	2005-01-27	Smithkline Beecham Corporation	Chemical compounds
US7501427B2 (en)	2003-08-14	2009-03-10	Array Biopharma, Inc.	Quinazoline analogs as receptor tyrosine kinase inhibitors
CN103664802B (zh) *	2003-08-14	2015-08-05	阿雷生物药品公司	作为受体酪氨酸激酶抑制剂的喹唑啉类似物
BRPI0413745A (pt)	2003-08-18	2006-10-24	Pfizer Prod Inc	horário mde dosagem para agentes anticancerìgenos erbb2
DE10337942A1 (de)	2003-08-18	2005-03-17	Merck Patent Gmbh	Aminobenzimidazolderivate
US7399865B2 (en)	2003-09-15	2008-07-15	Wyeth	Protein tyrosine kinase enzyme inhibitors
US20070032508A1 (en) *	2003-09-16	2007-02-08	Bradbury Robert H	Quinazoline derivatives as tyrosine kinase inhibitors
GB0321648D0 (en)	2003-09-16	2003-10-15	Astrazeneca Ab	Quinazoline derivatives
BRPI0416190A (pt)	2003-11-06	2007-01-23	Pfizer Prod Inc	combinações selectivas de inibidor erbb2/anticorpo anti erbb no tratamento do cancro
KR100735639B1 (ko)	2004-12-29	2007-07-04	한미약품 주식회사	암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
ATE507224T1 (de) *	2005-11-15	2011-05-15	Array Biopharma Inc	Verfahren und zwischenverbindungen zur herstellung von n4-phenyl-quinazolin-4-amin derivaten

2006
- 2006-11-15 AT AT09157031T patent/ATE507224T1/de active
- 2006-11-15 CA CA2755268A patent/CA2755268C/en active Active
- 2006-11-15 PL PL09157031T patent/PL2090575T3/pl unknown
- 2006-11-15 CN CN201210320423.2A patent/CN102887891B/zh active Active
- 2006-11-15 ES ES09157031T patent/ES2364901T3/es active Active
- 2006-11-15 SI SI200631044T patent/SI2090575T1/sl unknown
- 2006-11-15 KR KR1020087014416A patent/KR101086967B1/ko active Active
- 2006-11-15 ES ES06837728T patent/ES2335535T3/es active Active
- 2006-11-15 US US12/085,048 patent/US8648087B2/en active Active
- 2006-11-15 DK DK09157031.7T patent/DK2090575T3/da active
- 2006-11-15 JP JP2008541330A patent/JP5134548B2/ja active Active
- 2006-11-15 EP EP09157031A patent/EP2090575B1/en active Active
- 2006-11-15 RU RU2008118417/04A patent/RU2428421C2/ru active
- 2006-11-15 PT PT09157031T patent/PT2090575E/pt unknown
- 2006-11-15 DK DK06837728.2T patent/DK1971601T3/da active
- 2006-11-15 BR BRPI0618668-8A patent/BRPI0618668B1/pt active IP Right Grant
- 2006-11-15 RU RU2011122539/04A patent/RU2592703C9/ru active
- 2006-11-15 ZA ZA200804498A patent/ZA200804498B/xx unknown
- 2006-11-15 CN CNA2006800506892A patent/CN101356171A/zh active Pending
- 2006-11-15 WO PCT/US2006/044431 patent/WO2007059257A2/en active Application Filing
- 2006-11-15 AT AT06837728T patent/ATE446294T1/de active
- 2006-11-15 CA CA2632194A patent/CA2632194C/en active Active
- 2006-11-15 BR BR122018075851-1A patent/BR122018075851B1/pt active IP Right Grant
- 2006-11-15 EP EP06837728A patent/EP1971601B1/en active Active
- 2006-11-15 DE DE602006021645T patent/DE602006021645D1/de active Active
- 2006-11-15 DE DE602006009968T patent/DE602006009968D1/de active Active
- 2006-11-15 SI SI200630539T patent/SI1971601T1/sl unknown
- 2006-11-15 AU AU2006315383A patent/AU2006315383B2/en active Active
- 2006-11-15 PT PT06837728T patent/PT1971601E/pt unknown
- 2006-11-15 SG SG200902466-2A patent/SG152230A1/en unknown
- 2006-11-15 PL PL06837728T patent/PL1971601T3/pl unknown
2008
- 2008-06-10 NO NO20082598A patent/NO342413B1/no unknown
2010
- 2010-01-15 CY CY20101100043T patent/CY1110583T1/el unknown
- 2010-06-04 AU AU2010202330A patent/AU2010202330B2/en active Active
- 2010-09-06 JP JP2010198848A patent/JP5232841B2/ja active Active
2011
- 2011-07-15 CY CY20111100696T patent/CY1112754T1/el unknown
2013
- 2013-09-23 US US14/034,361 patent/US9693989B2/en active Active
2015
- 2015-06-02 IL IL239149A patent/IL239149A/en active IP Right Grant
2016
- 2016-11-15 IL IL248993A patent/IL248993B/en active IP Right Grant
2017
- 2017-05-19 US US15/599,867 patent/US20170252317A1/en not_active Abandoned
2018
- 2018-05-09 US US15/975,323 patent/US10780073B2/en active Active
2020
- 2020-07-27 US US16/940,091 patent/US20210008023A1/en not_active Abandoned
2021
- 2021-07-06 NL NL301113C patent/NL301113I2/nl unknown
- 2021-07-09 CY CY2021019C patent/CY2021019I2/el unknown
- 2021-07-09 FI FIC20210022C patent/FIC20210022I1/fi unknown
- 2021-07-20 LT LTPA2021516C patent/LTC1971601I2/lt unknown
- 2021-07-20 LU LU00217C patent/LUC00217I2/fr unknown
- 2021-07-20 FR FR21C1031C patent/FR21C1031I2/fr active Active
- 2021-07-29 HU HUS2100028C patent/HUS2100028I1/hu unknown
2022
- 2022-09-08 US US17/940,902 patent/US12171739B2/en active Active

Also Published As

Publication number	Publication date
AU2006315383B2 (en)	2011-06-02
DE602006009968D1 (de)	2009-12-03
BR122018075851B1 (pt)	2022-01-11
CA2755268A1 (en)	2007-05-24
IL248993B (en)	2018-11-29
ATE507224T1 (de)	2011-05-15
FR21C1031I2 (fr)	2022-07-15
NO20082598L (no)	2008-08-06
RU2011122539A (ru)	2012-12-10
SG152230A1 (en)	2009-05-29
KR101086967B1 (ko)	2011-11-29
US20170252317A1 (en)	2017-09-07
CA2632194C (en)	2012-01-03
IL239149A (en)	2016-11-30
LUC00217I2 (el)	2022-10-07
ZA200804498B (en)	2009-07-29
CA2755268C (en)	2013-12-31
CN101356171A (zh)	2009-01-28
WO2007059257A2 (en)	2007-05-24
EP2090575B1 (en)	2011-04-27
RU2008118417A (ru)	2009-12-27
AU2006315383A1 (en)	2007-05-24
AU2010202330B2 (en)	2012-07-19
JP5134548B2 (ja)	2013-01-30
RU2592703C2 (ru)	2016-07-27
EP1971601A2 (en)	2008-09-24
US20210008023A1 (en)	2021-01-14
CY2021019I2 (el)	2021-12-31
EP2090575A1 (en)	2009-08-19
CA2632194A1 (en)	2007-05-24
PL1971601T3 (pl)	2010-03-31
JP2010270154A (ja)	2010-12-02
ES2364901T3 (es)	2011-09-16
US20110034689A1 (en)	2011-02-10
LTPA2021516I1 (el)	2021-08-10
PT1971601E (pt)	2010-01-26
BRPI0618668B1 (pt)	2021-09-21
DK1971601T3 (da)	2010-02-08
CN102887891B (zh)	2016-03-09
AU2010202330A1 (en)	2010-07-01
NL301113I2 (nl)	2021-08-03
SI1971601T1 (sl)	2010-03-31
RU2592703C9 (ru)	2016-10-20
US8648087B2 (en)	2014-02-11
NL301113I1 (nl)	2021-07-01
HK1129678A1 (en)	2009-12-04
DK2090575T3 (da)	2011-05-23
RU2428421C2 (ru)	2011-09-10
US9693989B2 (en)	2017-07-04
ATE446294T1 (de)	2009-11-15
CY1110583T1 (el)	2015-04-29
FR21C1031I1 (el)	2021-08-27
NO342413B1 (no)	2018-05-22
ES2335535T3 (es)	2010-03-29
JP2009515988A (ja)	2009-04-16
IL248993A0 (en)	2017-01-31
CN102887891A (zh)	2013-01-23
HK1119174A1 (en)	2009-02-27
US20180271824A1 (en)	2018-09-27
FIC20210022I1 (fi)	2021-07-09
CY1112754T1 (el)	2016-02-10
EP1971601B1 (en)	2009-10-21
US20140023643A1 (en)	2014-01-23
HUS2100028I1 (hu)	2021-08-30
PL2090575T3 (pl)	2011-09-30
WO2007059257A8 (en)	2007-07-12
US10780073B2 (en)	2020-09-22
DE602006021645D1 (de)	2011-06-09
WO2007059257A3 (en)	2007-08-23
LTC1971601I2 (el)	2022-10-25
US12171739B2 (en)	2024-12-24
PT2090575E (pt)	2011-06-06
US20230142839A1 (en)	2023-05-11
KR20080070064A (ko)	2008-07-29
JP5232841B2 (ja)	2013-07-10
BRPI0618668A2 (pt)	2011-09-06
IL239149A0 (en)	2015-07-30
SI2090575T1 (sl)	2011-08-31

Publication	Publication Date	Title
CY2021019I1 (el)	2021-10-15	Παραγωγα ν4-φαινυλ-κιναζολινο-4-αμινης και σχετικες ενωσεις ως αναστολεις υποδοχεα κινασης τυροσινης τυπου i erbb για τη θεραπεια υπερπολλαπλασιαστικων ασθενειων
CY2022009I2 (el)	2022-05-27	Διυδροναφθυριδινες και σχετικες ενωσεις χρησιμες ως αναστολεις κινασης για τη θεραπεια πολλαπλασιαστικων ασθενειων
IL269976B (en)	2021-04-29	Intermediate compounds for the preparation of quinazolinones as inhibitors of human phophatidylinositol 3-kinase delta
CY2016015I1 (el)	2016-10-05	Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων
CY2013014I2 (el)	2015-08-05	Εναντιομερικως καθαρες αμινοετεροαρυλικες ενωσεις ως αναστολεις πρωτεϊνικης κινασης
ATE395346T1 (de)	2008-05-15	Chinazolinderivate als tyrosinkinaseinhibitoren
CY2015043I1 (el)	2016-04-13	Ενωσεις και συνθεσεις ως αναστολεις των πρωτεϊνικων κινασων
DE602007004092D1 (de)	2010-02-11	C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
SMAP200800022A (it)	2008-04-02	Benzimidazoli sostituiti come inibitori delle chinasi
DE602007014374D1 (de)	2011-06-16	Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
ATE520671T1 (de)	2011-09-15	Pyrimidin-harnstoff-derivate als kinase-hemmer
DE602005025733D1 (de)	2011-02-17	Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
BRPI0716844A2 (pt)	2013-10-22	Inidores de quinase úteis para o tratamento de doenças proliferativas
DK1881976T3 (da)	2013-02-04	Substituerede amidderivater som proteinkinaseinhibitorer
ATE527241T1 (de)	2011-10-15	Pyridiazinonderivate zur behandlung von tumoren
NO20070514L (no)	2007-03-12	Pyrrolotriazin kinase inhibitorer
ATE542823T1 (de)	2012-02-15	4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
EA200900798A1 (ru)	2010-10-29	Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
ATE404564T1 (de)	2008-08-15	Diazepinoindolderivate als kinaseinhibitoren
DE602005005810D1 (de)	2008-05-15	Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE486597T1 (de)	2010-11-15	3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
DE602006017574D1 (de)	2010-11-25	Als protein-kinase-inhibitoren nutzbare benzimidazole
IS8125A (is)	2005-11-11	Kínasólínafleiður til að meðhöndla krabbamein
DK2041093T3 (da)	2010-08-02	Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer
ZA200709000B (en)	2008-11-26	Substituted oxazole derivatives and their use as tyrosine kinase inhibitors